- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lepu Biopharma Co Ltd (2157)
Lepu Biopharma Co Ltd stock price live, this page displays HK 2157 stock exchange data. View the 2157 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lepu Biopharma Co Ltd real time stock price chart below.
What Is the Lepu Biopharma Co Ltd Stock Price Today?
The Lepu Biopharma Co Ltd stock price today is 4.49.
What Is the Stock Symbol for Lepu Biopharma Co Ltd?
The stock symbol for Lepu Biopharma Co Ltd is "2157."
What Stock Exchange Does Lepu Biopharma Co Ltd Trade On?
Lepu Biopharma Co Ltd is listed and trades on the Hong Kong stock exchange.
Is Lepu Biopharma Co Ltd a Good Stock to Buy?
Determining whether Lepu Biopharma Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2157 quote. (ISIN: CNE100004SM4)
What Is the Lepu Biopharma Co Ltd Stock Price Today?
The Lepu Biopharma Co Ltd stock price today is 4.49.
What Is the Stock Symbol for Lepu Biopharma Co Ltd?
The stock symbol for Lepu Biopharma Co Ltd is "2157."
What Stock Exchange Does Lepu Biopharma Co Ltd Trade On?
Lepu Biopharma Co Ltd is listed and trades on the Hong Kong stock exchange.
Is Lepu Biopharma Co Ltd a Good Stock to Buy?
Determining whether Lepu Biopharma Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2157 quote. (ISIN: CNE100004SM4)
Hong Kong
Currency in HKD
4.49
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.38
4.69
52 wk Range
3.55
10.50
2157 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.384.69
52 wk Range
3.5510.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2157 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
10.99
Upside
+144.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.99
(+144.82% Upside)
Earnings
Latest Release
Mar 25, 2026
EPS / Forecast
0.12 / --
Revenue / Forecast
468.93M / --
Compare 2157 to Peers and Sector
Metrics to compare | 2157 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2157PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 12.1x | −0.3x | |
PEG Ratio | 0.00 | 0.06 | 0.00 | |
Price/Book | 0.0x | 4.9x | 2.6x | |
Price / LTM Sales | 0.0x | 10.8x | 3.1x | |
Upside (Analyst Target) | 0.0% | 35.3% | 49.0% | |
Fair Value Upside | Unlock | 3.2% | 6.3% | Unlock |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-targeted ADC, which is in phase III trials for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC, which is in phase III clinical trial for treating pancreatic ductal adenocarcinoma. In addition, the company is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG002, which is in phase III trials to treat breast cancer, as well as HER2-positive. Further, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin’s lymphoma; MRG006A, MRG007, and CTM012 for the treatment of solid tumors. Lepu Biopharma Co., Ltd. was incorporated in 2018 and is headquartered in Shanghai, China. Lepu Biopharma Co., Ltd. operates as a subsidiary of Ningbo Houde Yimin Information Technology Co., Ltd.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Lepu Biopharma (2157) Stock Price Today?
The Lepu Biopharma stock price today is 4.49 HKD.
What Stock Exchange Does Lepu Biopharma Trade On?
Lepu Biopharma is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Lepu Biopharma?
The stock symbol for Lepu Biopharma is "2157."
What Is the Lepu Biopharma Market Cap?
As of today, Lepu Biopharma market cap is 8.10B HKD.
What Is Lepu Biopharma's Earnings Per Share (TTM)?
The Lepu Biopharma EPS (TTM) is 0.15.
From a Technical Analysis Perspective, Is 2157 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Lepu Biopharma Stock Split?
Lepu Biopharma has split 0 times.
How Many Employees Does Lepu Biopharma Have?
Lepu Biopharma has 710 employees.
What is the current trading status of Lepu Biopharma (2157)?
As of Aug 18, 2026, Lepu Biopharma (2157) is trading at a price of 4.49 HKD, with a previous close of 4.49 HKD. The stock has fluctuated within a day range of 4.38 HKD to 4.69 HKD, while its 52-week range spans from 3.55 HKD to 10.50 HKD.
What Is Lepu Biopharma (2157) Price Target According to Analysts?
The average 12-month price target for Lepu Biopharma is 10.99 HKD, with a high estimate of 10.99248989 HKD and a low estimate of 10.99248989 HKD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +144.82% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.